Danaher (NYSE:DHR) PT Raised to $290.00

Danaher (NYSE:DHR) had its price target raised by stock analysts at TD Cowen from $280.00 to $290.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the conglomerate’s stock. TD Cowen’s price target suggests a potential upside of 17.97% from the company’s previous close.

Other analysts have also issued research reports about the company. Robert W. Baird upped their price objective on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a report on Wednesday. Raymond James upped their price objective on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and upped their price objective for the company from $250.00 to $280.00 in a report on Wednesday, April 17th. Citigroup upped their price objective on Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. Finally, Royal Bank of Canada upped their price objective on Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Six research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, Danaher has an average rating of “Moderate Buy” and a consensus target price of $270.00.

Danaher Price Performance

Shares of NYSE DHR opened at $245.82 on Wednesday. The company has a market capitalization of $182.04 billion, a price-to-earnings ratio of 41.66, a price-to-earnings-growth ratio of 4.24 and a beta of 0.83. The business has a 50 day simple moving average of $248.94 and a 200-day simple moving average of $230.88. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. Danaher has a twelve month low of $182.09 and a twelve month high of $259.00.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.48% and a net margin of 16.78%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter in the prior year, the business posted $2.36 earnings per share. The company’s revenue for the quarter was down 2.6% compared to the same quarter last year. As a group, equities research analysts expect that Danaher will post 7.62 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Teri List sold 3,289 shares of the stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the sale, the director now directly owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The disclosure for this sale can be found here. In the last ninety days, insiders sold 84,132 shares of company stock valued at $21,022,795. Corporate insiders own 11.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of DHR. Cape Investment Advisory Inc. acquired a new position in Danaher in the 4th quarter worth about $25,000. Tsfg LLC increased its position in Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares during the last quarter. BKM Wealth Management LLC acquired a new position in Danaher in the 4th quarter worth about $27,000. Wetzel Investment Advisors Inc. acquired a new position in Danaher in the 4th quarter worth about $29,000. Finally, OFI Invest Asset Management acquired a new position in Danaher in the 3rd quarter worth about $30,000. 79.05% of the stock is owned by institutional investors and hedge funds.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.